No Cover Image

Journal article 978 views 215 downloads

Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy

Dimitri Reynard, Richard Hugtenburg Orcid Logo, François Estève, Jean-François Adam

Biomedical Physics & Engineering Express, Volume: 4, Issue: 4, Start page: 045015

Swansea University Author: Richard Hugtenburg Orcid Logo

Check full text

DOI (Published version): 10.1088/2057-1976/aac2f4

Abstract

The first trial applications of Contrast-Enhanced Synchrotron Stereotactic Radiation Therapy (SSRT) is underway since June 2012 at the European Synchrotron Radiation Facility (ESRF) in Grenoble (France). The phase I-II clinical trial is designed to test the feasibility and safety of SSRT through a d...

Full description

Published in: Biomedical Physics & Engineering Express
ISSN: 2057-1976
Published: 2018
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa40283
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2018-05-21T19:02:20Z
last_indexed 2019-08-28T20:24:46Z
id cronfa40283
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2019-08-28T15:46:08.6537056</datestamp><bib-version>v2</bib-version><id>40283</id><entry>2018-05-21</entry><title>Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy</title><swanseaauthors><author><sid>efd2f52ea19cb047e01a01e6fa6fa54c</sid><ORCID>0000-0003-0352-9607</ORCID><firstname>Richard</firstname><surname>Hugtenburg</surname><name>Richard Hugtenburg</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2018-05-21</date><deptcode>MEDP</deptcode><abstract>The first trial applications of Contrast-Enhanced Synchrotron Stereotactic Radiation Therapy (SSRT) is underway since June 2012 at the European Synchrotron Radiation Facility (ESRF) in Grenoble (France). The phase I-II clinical trial is designed to test the feasibility and safety of SSRT through a dose escalation protocol. Contrast enhanced radiotherapy achieves localized dose enhancement due to higher photoelectric effect rate in the target. This increase is obtained through the preferential uptake of high-Z media (iodine) in the tumoral area combined with irradiations with medium energy synchrotron x-rays. In vivo dosimetry (i.e. experimental dosimetry in real time during the treatment) would be a serious added value to the project, in terms of online dose monitoring and quality control. It is challenging to perform in vivo dosimetry with the currently available conventional clinical techniques. In this work we investigated a method using x-ray fluorescence detection to derive the iodine concentration contained in a tumor during the treatment of a patient, as a first step towards in vivo dosimetry. A mean iodine concentration of 0.33 &#xB1; 0.22 mg/ml has been retrieved in the tumor of the patient compared to 2 mg/ml expected would correspond to 3% local dose enhancement in the tumor. Further work will be performed to improve the attenuation correction method. The expected amount of iodine should be 2 mg/ml in the tumor (20% dose enhancement). This method is suitable to detect iodine in the target but has some problem in quantifying the real amount of iodine present during the irradiation.</abstract><type>Journal Article</type><journal>Biomedical Physics &amp; Engineering Express</journal><volume>4</volume><journalNumber>4</journalNumber><paginationStart>045015</paginationStart><publisher/><issnElectronic>2057-1976</issnElectronic><keywords/><publishedDay>17</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2018</publishedYear><publishedDate>2018-05-17</publishedDate><doi>10.1088/2057-1976/aac2f4</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical Physics</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDP</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2019-08-28T15:46:08.6537056</lastEdited><Created>2018-05-21T14:55:08.9324515</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Dimitri</firstname><surname>Reynard</surname><order>1</order></author><author><firstname>Richard</firstname><surname>Hugtenburg</surname><orcid>0000-0003-0352-9607</orcid><order>2</order></author><author><firstname>Fran&#xE7;ois</firstname><surname>Est&#xE8;ve</surname><order>3</order></author><author><firstname>Jean-Fran&#xE7;ois</firstname><surname>Adam</surname><order>4</order></author></authors><documents><document><filename>0040283-22052018121206.pdf</filename><originalFilename>Reynardetal_2018_Biomed._Phys._Eng._Express_10.1088_2057-1976_aac2f4(1).pdf</originalFilename><uploaded>2018-05-22T12:12:06.7570000</uploaded><type>Output</type><contentLength>1017557</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><embargoDate>2019-05-17T00:00:00.0000000</embargoDate><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2019-08-28T15:46:08.6537056 v2 40283 2018-05-21 Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy efd2f52ea19cb047e01a01e6fa6fa54c 0000-0003-0352-9607 Richard Hugtenburg Richard Hugtenburg true false 2018-05-21 MEDP The first trial applications of Contrast-Enhanced Synchrotron Stereotactic Radiation Therapy (SSRT) is underway since June 2012 at the European Synchrotron Radiation Facility (ESRF) in Grenoble (France). The phase I-II clinical trial is designed to test the feasibility and safety of SSRT through a dose escalation protocol. Contrast enhanced radiotherapy achieves localized dose enhancement due to higher photoelectric effect rate in the target. This increase is obtained through the preferential uptake of high-Z media (iodine) in the tumoral area combined with irradiations with medium energy synchrotron x-rays. In vivo dosimetry (i.e. experimental dosimetry in real time during the treatment) would be a serious added value to the project, in terms of online dose monitoring and quality control. It is challenging to perform in vivo dosimetry with the currently available conventional clinical techniques. In this work we investigated a method using x-ray fluorescence detection to derive the iodine concentration contained in a tumor during the treatment of a patient, as a first step towards in vivo dosimetry. A mean iodine concentration of 0.33 ± 0.22 mg/ml has been retrieved in the tumor of the patient compared to 2 mg/ml expected would correspond to 3% local dose enhancement in the tumor. Further work will be performed to improve the attenuation correction method. The expected amount of iodine should be 2 mg/ml in the tumor (20% dose enhancement). This method is suitable to detect iodine in the target but has some problem in quantifying the real amount of iodine present during the irradiation. Journal Article Biomedical Physics & Engineering Express 4 4 045015 2057-1976 17 5 2018 2018-05-17 10.1088/2057-1976/aac2f4 COLLEGE NANME Medical Physics COLLEGE CODE MEDP Swansea University 2019-08-28T15:46:08.6537056 2018-05-21T14:55:08.9324515 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Dimitri Reynard 1 Richard Hugtenburg 0000-0003-0352-9607 2 François Estève 3 Jean-François Adam 4 0040283-22052018121206.pdf Reynardetal_2018_Biomed._Phys._Eng._Express_10.1088_2057-1976_aac2f4(1).pdf 2018-05-22T12:12:06.7570000 Output 1017557 application/pdf Accepted Manuscript true 2019-05-17T00:00:00.0000000 true eng
title Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy
spellingShingle Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy
Richard Hugtenburg
title_short Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy
title_full Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy
title_fullStr Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy
title_full_unstemmed Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy
title_sort Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy
author_id_str_mv efd2f52ea19cb047e01a01e6fa6fa54c
author_id_fullname_str_mv efd2f52ea19cb047e01a01e6fa6fa54c_***_Richard Hugtenburg
author Richard Hugtenburg
author2 Dimitri Reynard
Richard Hugtenburg
François Estève
Jean-François Adam
format Journal article
container_title Biomedical Physics & Engineering Express
container_volume 4
container_issue 4
container_start_page 045015
publishDate 2018
institution Swansea University
issn 2057-1976
doi_str_mv 10.1088/2057-1976/aac2f4
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description The first trial applications of Contrast-Enhanced Synchrotron Stereotactic Radiation Therapy (SSRT) is underway since June 2012 at the European Synchrotron Radiation Facility (ESRF) in Grenoble (France). The phase I-II clinical trial is designed to test the feasibility and safety of SSRT through a dose escalation protocol. Contrast enhanced radiotherapy achieves localized dose enhancement due to higher photoelectric effect rate in the target. This increase is obtained through the preferential uptake of high-Z media (iodine) in the tumoral area combined with irradiations with medium energy synchrotron x-rays. In vivo dosimetry (i.e. experimental dosimetry in real time during the treatment) would be a serious added value to the project, in terms of online dose monitoring and quality control. It is challenging to perform in vivo dosimetry with the currently available conventional clinical techniques. In this work we investigated a method using x-ray fluorescence detection to derive the iodine concentration contained in a tumor during the treatment of a patient, as a first step towards in vivo dosimetry. A mean iodine concentration of 0.33 ± 0.22 mg/ml has been retrieved in the tumor of the patient compared to 2 mg/ml expected would correspond to 3% local dose enhancement in the tumor. Further work will be performed to improve the attenuation correction method. The expected amount of iodine should be 2 mg/ml in the tumor (20% dose enhancement). This method is suitable to detect iodine in the target but has some problem in quantifying the real amount of iodine present during the irradiation.
published_date 2018-05-17T03:51:18Z
_version_ 1763752519293468672
score 11.013731

Similar Items